Leqvio® (inclisiran)
Hypercholesterolemia
Key Facts
About Novartis
Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.
View full company profileAbout Alnylam Pharmaceuticals
Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.
View full company profileTherapeutic Areas
Other Hypercholesterolemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VXX-401 | Vaxxinity | Phase 1 |
| Atorvastatin Oral Liquid Suspension | CMP Pharma | Approved |
| AFFITOPE® AT04 (licensed to Frontier Biotech) | AFFiRiS | Phase 1 |
| AQR-008 | Aqur Biosciences | Pre-clinical |
| MK-0616 | Merck | Phase 3 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase III |
| IBI-306 | Innovent Biologics | NDA Submitted |
| Inusiran (AK102) | Akeso | Approved |
| Obicetrapib + Ezetimibe FDC | NewAmsterdam Pharma Company | Phase 3 |